A study published recently in the AACR’s journal Cancer Discovery addresses the burgeoning question of the utility of high-throughput...
This time last year there were no immune checkpoint inhibitors approved by the U.S. Food and Drug Administration (FDA)...
After being diagnosed with cancer, some patients consider getting a second opinion. This may involve a pathologist confirming a...
Last week, a flurry of U.S. Food and Drug Administration (FDA) oncology approvals concluded with the approval of the...
Earlier this week, the U.S. Food and Drug Administration (FDA) announced that it had approved a new immune checkpoint...
Members of the AACR Project GENIE consortium presented their first analyses of the data during the Pan-Cancer Genomic Analysis...
May is National Cancer Research Month, during which the American Association for Cancer Research partners with advocacy groups, cancer...
On Thursday, the U.S. Food and Drug Administration (FDA) expanded the use of the antiangiogenic therapeutic regorafenib (Stivarga) to...
The American Association for Cancer Research (AACR) Annual Meeting 2017 brought some of the world’s greatest scientific minds to...
Last month, U.S. Rep. Donald Payne Jr. (D-New Jersey), led a roundtable discussion at University Hospital in Newark, New...